Hydrokortison Dak (Hydrocortisone)

Hydrokortison Dak is indicated for several clinical situations where glucocorticoid activity is required.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute inflammatory disorders such as severe dermatitis or arthritis flares.
• Treatment of systemic allergic reactions when rapid anti‑inflammatory action is needed.
• Adjunctive therapy in certain autoimmune conditions under specialist guidance.
• Short‑term control of hormone‑dependent inflammation in postoperative settings.

• Hydrocortisone penetrates cell membranes and binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus, where it interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokine genes. This genomic effect reduces leukocyte infiltration, stabilizes lysosomal membranes, and decreases capillary permeability, collectively providing glucocorticoid‑mediated anti‑inflammatory and immunosuppressive actions.

Like all systemic corticosteroids, hydrocortisone may cause adverse reactions that vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort or nausea.
• Transient elevation of blood glucose levels.
• Mood changes such as irritability or insomnia.

Serious

• Severe hyperglycemia or new‑onset diabetes.
• Significant hypertension or fluid retention.
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis leading to adrenal crisis on abrupt discontinuation.

Healthcare providers should evaluate several factors before initiating Hydrokortison Dak to minimize risks.

• Assess for active infections; systemic corticosteroids can worsen bacterial, viral, or fungal diseases.
• Screen for uncontrolled diabetes or hypertension, as glucocorticoids may exacerbate these conditions.
• Use with caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
• Evaluate bone health, especially in long‑term therapy, due to risk of osteoporosis.
• Consider potential fetal risk; the pregnancy category is not established, so use only if benefits outweigh risks.
• Monitor electrolyte balance, particularly sodium and potassium, during prolonged treatment.
• Avoid abrupt cessation after extended use to prevent adrenal insufficiency.

Hydrokortison Dak can alter the pharmacokinetics or pharmacodynamics of several other medicines.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure.
• Co‑administration with other systemic glucocorticoids, which can increase the risk of systemic corticosteroid toxicity.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients at high risk for gastrointestinal bleeding.

Use with caution

• Anticoagulants such as warfarin, where hydrocortisone may enhance anticoagulant effect.
• Antidiabetic agents; corticosteroids can raise blood glucose, requiring dose adjustments.
• Vaccines, especially live attenuated vaccines, as immunosuppression may diminish vaccine efficacy.
• Diuretics, which may potentiate fluid and electrolyte disturbances.